Mayer, Erica L.
Tayob, Nabihah
Ren, Siyang
Savoie, Jennifer J.
Spigel, David R.
Burris, Howard A. III
Ryan, Paula D.
Harris, Lyndsay N.
Winer, Eric P.
Burstein, Harold J. http://orcid.org/0000-0003-1963-8162
Clinical trials referenced in this document:
Documents that mention this clinical trial
A randomized phase II study of metronomic cyclophosphamide and methotrexate (CM) with or without bevacizumab in patients with advanced breast cancer
https://doi.org/10.1007/s10549-023-07167-9
Funding for this research was provided by:
National Cancer Institute
National Institutes of Health DF/HCC SPORE Grant (NIH Grant Number: P50CA168504)
Genentech
Article History
Received: 22 August 2023
Accepted: 24 October 2023
First Online: 29 November 2023
Declarations
:
: ELM reports a consulting role with Lilly, Novartis, AstraZeneca, and Gilead. HAB reports research grants paid to institution from Abbvie, Agios, ARMO Biosciences, Array BioPharma, Arvinas, AstraZeneca, Bayer, BeiGene, BioAtla, BioMed Valley Discoveries, BioTheryX, Boehringer Ingelheim, Bristol Myers Squibb, CALGB, Celgene, CicloMed, Coordination Pharmaceuticals, eFFECTOR Therapeutics, Lilly, EMD Serono, Roche/Genentech, GlaxoSmithKline, Gossamer Bio, Harpoon Therapeutics, Hengrui Therapeutics, InCyte, Janssen, Jounce Therapeutics, Kymab, MacroGenics, MedImmune, Merck, Millennium/Takeda, Moderna, NGM Biopharmaceuticals, Novartis, Pfizer, Revolution Medicines, Ryvu Therapeutics, Foundation Medicine, SeaGen, Tesaro, TG Therapeutics, Varastem, Vertex, XBiotech, Zymeworks; Consulting—Paid to Institution from GRAIL, Roche, Vincerx Pharma; Non-Compensated Consulting from Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Novartis, and TG Therapeutics. DRS reports research grants paid to institution from Abbvie, Aeglea BioTherapeutics, Agios, Amgen, AnHeart Therapeutics, Apollomics, Arcus, Arrys Therapeutics, Ascendis Pharma, Asher Biotherapeutics, Astellas, AstraZeneca, Bayer, BeiGene, Bind Therapeutics, BioNTech, Blueprint Medicine, Boehringer Ingelheim, Bristol Myers Squibb, Calithera, Celgene, Celldex, Clovis, Cyteir Therapeutics, Daiichi Sankyo, Eisai, Elevation Oncology, Endeavor, Erasca, Faeth Therapeutics, Fujifilm Pharmaceuticals, G1 Therapeutics, Roche/Genentech, Gilead Sciences, GlaxoSmithKline, GRAIL, Hutchison MediPharma, lmClose Systems, lncyte, Ipsen, Janssen, Jazz Pharmaceuticals, Kronos Bio, Lilly, Loxo Oncology, Lyell lmmunopharma, MacroGenics, Medlmmune, Merck, Millennium Pharmaceuticals, Moderna, Molecular Template, Monte Rosa Therapeutics, Nektar, Neon Therapeutics, Novartis, Novocure, Peloton Therapeutics, PureTech Health, Razor Genomics, Repare Therapeutics, Rgenix (Inspirna), SeaGen, Shenzhen Chipscreen Biosciences, Stemline Therapeutics, Strata Oncology, Synthekine, Taiho, Tango Therapeutics, Tarveda, Tesaro, Tizona Therapeutics, Transgene, UT Southwestern, Verastem, and Zai Laboratory; and payment made to institution for consulting work conducted for Abbvie, AstraZeneca, BeiGene, Bristol Myers Squibb, Evidera, GlaxoSmithKline, Ipsen Biopharmaceuticals, Janssen, Jazz Pharmaceuticals, Lilly, Molecular Templates, Monte Rosa Therapeutics, Novartis, Novosure, Pfizer, Regeneron Pharmaceuticals, Roche/Genentech, and Sanofi-Aventis. The remaining authors declare no competing interests.
: This study was conducted in line with the principles of the Declaration of Helsinki. Approval was granted by the Dana-Farber/Harvard Cancer Center (DF/HCC) Institutional Review Board (IRB). All participants provided written informed consent before being enrolled on the study.